|
CWF19L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62636570877339E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.9031893796564E-14 |
| Normal-vs-Stage2 |
3.25939999989977E-07 |
| Normal-vs-Stage3 |
9.90985071780415E-13 |
| Normal-vs-Stage4 |
2.24786855795855E-12 |
| Stage1-vs-Stage2 |
5.869800E-01 |
| Stage1-vs-Stage3 |
4.240200E-01 |
| Stage1-vs-Stage4 |
5.005500E-02 |
| Stage2-vs-Stage3 |
3.171200E-01 |
| Stage2-vs-Stage4 |
6.260000E-02 |
| Stage3-vs-Stage4 |
2.174200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.30224736444507E-12 |
| Normal-vs-AfricanAmerican |
1.39449995995022E-09 |
| Normal-vs-Asian |
6.43929354282591E-15 |
| Caucasian-vs-AfricanAmerican |
5.551900E-02 |
| Caucasian-vs-Asian |
3.801300E-03 |
| AfricanAmerican-vs-Asian |
7.428200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.34738919810707E-12 |
| Normal-vs-Female |
1.62903024403249E-12 |
| Male-vs-Female |
5.553000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.72384329033548E-12 |
| Normal-vs-Age(41-60Yrs) |
2.67563748934663E-14 |
| Normal-vs-Age(61-80Yrs) |
3.57910034942677E-10 |
| Normal-vs-Age(81-100Yrs) |
1.739890E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.531000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.174800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.210200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.206600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.328600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.838200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.222500E-02 |
| Classical-VS-Follicular |
5.015800E-02 |
| Classical-VS-Other |
5.693600E-02 |
| Classical-VS-Normal |
1.95055083196394E-12 |
| Tall-VS-Follicular |
5.404800E-01 |
| Tall-VS-Other |
4.993800E-01 |
| Tall-VS-Normal |
2.2531998489228E-10 |
| Follicular-VS-Other |
4.098400E-01 |
| Follicular-VS-Normal |
1.95320426499279E-11 |
| Other-VS-Normal |
2.08159999999236E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.35219613284221E-11 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
8.25850000000239E-05 |
|
|
